AI Article Synopsis

  • - Human T-lymphotropic virus (HTLV-1) affects over 10 million people worldwide and is associated with two main diseases: Adult T cell Leukemia-Lymphoma (ATLL) and HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
  • - A systematic review analyzed 20 studies involving 1,420 cases and found that IL-17 cytokine levels were higher in HAM/TSP patients but reduced in those with ATLL.
  • - The findings suggest that enhancing the RORC/IL-17 signaling pathway may help ATLL patients, while anti-IL-17 therapies could improve outcomes for those suffering from HAM/TSP and other HTLV

Article Abstract

Background: Human T-lymphotropic virus (HTLV-1) is a neglected virus with worldwide distribution of over 10 million people and is the cause of two main associated diseases Adult T cell Leukemia-Lymphoma (ATLL), and HTLV-1-associated Myelopathy/Tropical Spastic paraparesis (HAM/TSP). The IL-17 cytokine family plays a crucial role in the host immunity against HTLV-1 and the development of associated disease. A systematic review was conducted to analyze all research reporting on the levels or expression of the IL-17 HTLV-1 infection and associated diseases.

Methods: The literature search was conducted in electronic databases including PubMed/Medline and Web of Sciences until January 31st, 2024, followed by the PRISMA guidelines.

Results: Our search revealed 20 eligible articles to be included in our study. The total number of cases studied was 1420, of which 386 were carriers without any symptoms, and were 176 ATLL and 237 HAM/TSP. The IL-17 cytokine family production or mRNA expression was higher in HAM/TSP patients but showed a trend toward reduction in the case of ATLL.

Conclusions: Our results showed that while The IL-17 cytokine family plays a significant role in the immunopathogenesis of disease and clinical status of patients with inflammatory disorders such as HAM/TSP, IL-17 production is diminished and the RORC/IL-17 signaling pathway is downregulated during ATLL. Our data suggest that boosting the RORC/IL-17 signaling pathway in ATLL and using anti-IL-17 agents in HAM/TSP and other HTLV-related inflammatory conditions might benefit patients and improve their outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2024.156710DOI Listing

Publication Analysis

Top Keywords

cytokine family
16
ham/tsp il-17
12
il-17 cytokine
12
htlv-1 infection
8
infection associated
8
associated diseases
8
family plays
8
rorc/il-17 signaling
8
signaling pathway
8
ham/tsp
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!